Dr. rer. nat. Franz Josef Zimmer. Zugelassener Patentanwalt 1993, European Patent Attorney 1995, European Trademark Attorney 1996. Technische Ausbildung: Universität Tübingen: Diplom in Biochemie 1985; Ludwig-Maximilians-Universität München, Promotion in Immungenetik 1989. Mitgliedschaften: FICPI, LES, AIPLA, GBM (Gesellschaft für Biochemie und Molekularbiologie), Mitglied der Redaktion des „Biotechnology Law Report (BLR)“. Veröffentlichungen: "Protection of Biotechnological Matter under European and German Law", A Handbook for Applicants, Goldbach, Vogelsang, Zimmer, Wiley-VCH, 1997; “Biotechnology Directive-European Patent Office-ESTs: Are Expressed Sequence Tags Patentable under the European Patent Convention? A Practitioner's View”, Franz-Joseph Zimmer, Biotechnology Law Report, August 1999: 304-312; “Europe-Patents-Plant Varieties: New Rules of the European Patent Office for Biotechnological Inventions”, Franz-Josef Zimmer, Biotechnology Law Report, December 1999: 511-516; “Method-of-Treatment Inventions under the EPC: What Kind of Protection Can You Get?”, Franz-Josef Zimmer, Thomas Friede, Biotechnology Law Report, June 2000: 315-322; “Standard for Valid Priority Claim Defined by EPO Enlarged Board of Appeal”, Franz Josef Zimmer, Biotechnology Law Report, December 2001: 867-870; “Patentability of Diagnostic Methods Under the EPC: A New Referral to the Enlarged Board of Appeal by the President of the EPO”, Franz-Josef Zimmer, Ulrike Langheinrich, Biotechnology Law Report, August 2004: 402-413; “Admissibility of a Disclaimer in Patent Claims: The Standard as Set by the EPO Enlarged Board of Appeal Decision G01/03”, Franz-Josef Zimmer, Svenja Sethmann, Biotechnology Law Report, October 2004: 548-555; “Act Implementing the Directive on the Legal Protection of Biotechnological Inventions in Germany (BioPatG)”, Franz-Josef Zimmer, Svenja Sethmann, Biotechnology Law Report, October 2005: 561-566; “Patentability of Diagnostic Methods Under the Most Recent Decision of the Enlarged Board of Appeal G 1/04”, Franz-Josef Zimmer, Qi Wang, Biotechnology Law Report, August 2006: 384-387; “New Referral to the Enlarged Board of Appeal Concerning the Patentability of Embryonic Stem Cells”, Franz-Josef Zimmer, Biotechnology Law Report, August 2006: 388-388; “Stem Cell Patents: Does T 0866/01 (“Euthanasia Compositions”) of An Appeal Board of The EPO Provide The Answers for The Enlarged Board of Appeal Case G 2/06 (“Primate Embryonic Stem Cells”)?”, Franz-Josef Zimmer, George Seisenberger, Biotechnology Law Report, February 2007: 1-4; “Applicant Friendliness of the European Patent Office for Second Medical Use Claims: A Mixed Blessing”, Dr. Franz-Josef Zimmer, Dr. Steven Zeman, Biotechnology Law Report, August 2007: 341-348; “Chemical Selection Inventions in the EPO and Germany: Continued Divergence in Legal Interpretation”, Dr. Steven M. Zeman, Dr. Franz-Josef Zimmer, Biotechnology Law Report, August 2008: 293-303; “The Olanzapine Patent Dispute: German Court Grants a Preliminary Injunction on a Patent Invalidated by the First-Instance Federal Patent Court”, Gerhard Barth, Dr. Franz-Josef Zimmer, Biotechnology Law Report, December 2008: 532-536; “The EPO's Decision G 2/06 on the Patentability of Human Embryonic Stem Cells: Sounding the Bell for the Next Round?”, Rainer Plaggenborg, Franz-Josef Zimmer, Biotechnology Law Report, June 2009: 332-337; “When Is a Process for the Production of Plants “Essentially Biological”? - Decisions of the Enlarged Board of Appeal (G1/08 and G2/07)”, Dr. Franz-Josef Zimmer, Dr. Benjamin Quest, Biotechnology Law Report, August 2011: 459-464; “EPO Enlarged Board of Appeal Decides on Dosage Regimens (G2/08) and Treatment by Surgery (G1/07)”, Franz-Josef Zimmer, Benjamin Quest, Biotechnology Law Report, October 2010: 485-491. Sprachen: Deutsch, Englisch, Französisch. zimmer@grunecker.de